Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

427 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.
Del Principe MI, Buccisano F, Maurillo L, Sconocchia G, Cefalo M, Consalvo MI, Sarlo C, Conti C, De Santis G, De Bellis E, Di Veroli A, Palomba P, Attrotto C, Zizzari A, Paterno G, Voso MT, Del Poeta G, Lo-Coco F, Arcese W, Amadori S, Venditti A. Del Principe MI, et al. Among authors: amadori s. Mediterr J Hematol Infect Dis. 2016 Oct 20;8(1):e2016052. doi: 10.4084/MJHID.2016.052. eCollection 2016. Mediterr J Hematol Infect Dis. 2016. PMID: 27872732 Free PMC article. Review.
Treatment of acute myeloid leukemia with 20-30% bone marrow blasts.
Maurillo L, Buccisano F, Del Principe MI, Sarlo C, Di Caprio L, Ditto C, Giannotti F, Nasso D, Ceresoli E, Postorino M, Refrigeri M, Amadori S, Venditti A. Maurillo L, et al. Among authors: amadori s. Mediterr J Hematol Infect Dis. 2013 Jun 3;5(1):e2013032. doi: 10.4084/MJHID.2013.032. Print 2013. Mediterr J Hematol Infect Dis. 2013. PMID: 23795270 Free PMC article.
Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia.
Maurillo L, Buccisano F, Piciocchi A, Del Principe MI, Sarlo C, Di Veroli A, Panetta P, Irno-Consalvo M, Nasso D, Ditto C, Refrigeri M, De Angelis G, Cerretti R, Arcese W, Sconocchia G, Lo-Coco F, Amadori S, Venditti A. Maurillo L, et al. Among authors: amadori s. Am J Hematol. 2015 Feb;90(2):125-31. doi: 10.1002/ajh.23893. Epub 2014 Nov 24. Am J Hematol. 2015. PMID: 25377359 Free article. Clinical Trial.
Central nervous system involvement in adult acute lymphoblastic leukemia: diagnostic tools, prophylaxis, and therapy.
Del Principe MI, Maurillo L, Buccisano F, Sconocchia G, Cefalo M, De Santis G, Di Veroli A, Ditto C, Nasso D, Postorino M, Refrigeri M, Attrotto C, Del Poeta G, Lo-Coco F, Amadori S, Venditti A. Del Principe MI, et al. Among authors: amadori s. Mediterr J Hematol Infect Dis. 2014 Nov 1;6(1):e2014075. doi: 10.4084/MJHID.2014.075. eCollection 2014. Mediterr J Hematol Infect Dis. 2014. PMID: 25408861 Free PMC article. Review.
Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia.
Buccisano F, Maurillo L, Del Principe MI, Di Veroli A, De Bellis E, Biagi A, Zizzari A, Rossi V, Rapisarda V, Amadori S, Voso MT, Lo-Coco F, Arcese W, Venditti A. Buccisano F, et al. Among authors: amadori s. Expert Rev Hematol. 2018 Apr;11(4):307-313. doi: 10.1080/17474086.2018.1447378. Epub 2018 Mar 7. Expert Rev Hematol. 2018. PMID: 29495904 Review.
Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients.
Buccisano F, Maurillo L, Piciocchi A, Del Principe MI, Sarlo C, Cefalo M, Ditto C, Di Veroli A, De Santis G, Irno Consalvo M, Fraboni D, Panetta P, Palomba P, Attrotto C, Del Poeta G, Sconocchia G, Lo-Coco F, Amadori S, Venditti A. Buccisano F, et al. Among authors: amadori s. Ann Hematol. 2015 Aug;94(8):1319-26. doi: 10.1007/s00277-015-2364-5. Epub 2015 Apr 14. Ann Hematol. 2015. PMID: 25869029
427 results